Alnylam Pharmaceuticals, Inc. $ALNY Shares Acquired by Casdin Capital LLC

Posted by Francis Steltz on Jun 18th, 2026

Casdin Capital LLC grew its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 36.4% in the 4th quarter, HoldingsChannel reports. The firm owned 75,000 shares of the biopharmaceutical company’s stock after acquiring an additional 20,000 shares during the quarter. Alnylam Pharmaceuticals makes up about 1.9% of Casdin Capital LLC’s portfolio, making the stock its 13th biggest position. Casdin Capital LLC’s holdings in Alnylam Pharmaceuticals were worth $29,824,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the business. iA Global Asset Management Inc. increased its holdings in shares of Alnylam Pharmaceuticals by 979.5% during the 4th quarter. iA Global Asset Management Inc. now owns 17,780 shares of the biopharmaceutical company’s stock valued at $7,070,000 after acquiring an additional 16,133 shares during the last quarter. Perpetual Ltd bought a new position in Alnylam Pharmaceuticals in the 4th quarter valued at $2,004,000. Linden Advisors LP acquired a new stake in shares of Alnylam Pharmaceuticals in the 3rd quarter valued at $6,550,000. WINTON GROUP Ltd grew its stake in shares of Alnylam Pharmaceuticals by 92.5% during the third quarter. WINTON GROUP Ltd now owns 6,800 shares of the biopharmaceutical company’s stock worth $3,101,000 after purchasing an additional 3,267 shares during the period. Finally, Elo Mutual Pension Insurance Co grew its stake in shares of Alnylam Pharmaceuticals by 26.5% during the third quarter. Elo Mutual Pension Insurance Co now owns 17,865 shares of the biopharmaceutical company’s stock worth $8,146,000 after purchasing an additional 3,738 shares during the period. 92.97% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages have recently commented on ALNY. Jefferies Financial Group restated a “hold” rating and issued a $330.00 price target (down from $522.00) on shares of Alnylam Pharmaceuticals in a report on Monday, March 16th. Wall Street Zen raised Alnylam Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 13th. Chardan Capital reiterated a “buy” rating and set a $425.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Wednesday, March 25th. Truist Financial lowered their target price on Alnylam Pharmaceuticals from $515.00 to $505.00 and set a “buy” rating for the company in a research report on Monday, April 13th. Finally, Royal Bank Of Canada reduced their target price on Alnylam Pharmaceuticals from $450.00 to $445.00 and set an “outperform” rating for the company in a research note on Friday, May 1st. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat.com, Alnylam Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $463.13.

Get Our Latest Stock Analysis on Alnylam Pharmaceuticals

Alnylam Pharmaceuticals Trading Up 0.3%

Shares of Alnylam Pharmaceuticals stock opened at $282.72 on Thursday. The firm’s 50 day simple moving average is $302.00 and its two-hundred day simple moving average is $339.75. Alnylam Pharmaceuticals, Inc. has a 12-month low of $276.94 and a 12-month high of $495.55. The firm has a market capitalization of $37.75 billion, a price-to-earnings ratio of 77.25 and a beta of 0.29. The company has a current ratio of 3.13, a quick ratio of 3.06 and a debt-to-equity ratio of 0.94.

Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) last announced its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share for the quarter, beating analysts’ consensus estimates of $0.87 by $1.12. Alnylam Pharmaceuticals had a net margin of 11.72% and a return on equity of 85.76%. The business had revenue of $1.17 billion during the quarter, compared to analysts’ expectations of $1.12 billion. During the same period last year, the business earned ($0.44) earnings per share. The business’s revenue for the quarter was up 96.4% on a year-over-year basis. Analysts predict that Alnylam Pharmaceuticals, Inc. will post 7.47 EPS for the current year.

Insider Activity at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, insider Melissa Mclaughlin sold 2,286 shares of Alnylam Pharmaceuticals stock in a transaction on Monday, April 6th. The shares were sold at an average price of $330.42, for a total value of $755,340.12. Following the completion of the transaction, the insider owned 9,443 shares of the company’s stock, valued at $3,120,156.06. The trade was a 19.49% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director David E. I. Pyott sold 3,830 shares of the business’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $299.18, for a total value of $1,145,859.40. Following the sale, the director owned 1,582 shares in the company, valued at approximately $473,302.76. The trade was a 70.77% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 7,740 shares of company stock valued at $2,420,214 in the last ninety days. 0.86% of the stock is owned by corporate insiders.

About Alnylam Pharmaceuticals

(Free Report)

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.